Affymax, Inc. Declares Special Cash Distribution, Payable on or About December 23, 2014; Appoints Jonathan M. Couchman as Class I Director, President and Chief Executive Officer
November 26, 2014 at 04:15 pm EST
Share
Affymax, Inc. announced that its board of directors has declared a special cash distribution to shareholders in the amount of $0.05 per share. The special cash distribution will be paid to shareholders of record at the close of business on December 2, 2014, the record date, on or about December 23, 2014.
The board has also appointed Jonathan M. Couchman as a Class I director of the company and as its President and Chief Executive Officer, and the remaining members of the board have resigned. The company, under the leadership of Mr. Couchman, will continue its evaluation of strategic alternatives. Jonathan M. Couchman serves as Chairman of the Board, Chief Executive Officer and Chief Financial Officer of Xstelos Holdings, Inc., and Myrexis, Inc. and previously served as Director of Golf Trust of America, during its evaluation of strategic alternatives, which culminated in the reverse merger of privately owned Pernix Therapeutics Holdings, Inc. into Golf Trust of America, effective March 9, 2010.
Affymax, Inc. is a biopharmaceutical company. The Companyâs product OMONTYS (peginesatide) is for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. OMONTYS is a synthetic, peptide-based erythropoiesis stimulating agent (ESA), designed to stimulate production of red blood cells. The Company has a collaboration to develop and commercialize peginesatide with Takeda Pharmaceutical Company Limited. In March 2012, the Food and Drug Administration (FDA) approved the Companyâs product, OMONTYS.
Affymax, Inc. Declares Special Cash Distribution, Payable on or About December 23, 2014; Appoints Jonathan M. Couchman as Class I Director, President and Chief Executive Officer
AFFYMAX, INC. 
